[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Peking University Aerospace Center Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100650966","safety-and-efficacy-of-microwave-ablation-alone-versus-microwave-ablation-combined-with-chemical-ablation-in-the-treatment-of-uterine-fibroids-a-prospective-multicenter-study-100650966",false,"NCT07754877","Safety and Efficacy of Microwave Ablation Alone Versus Microwave Ablation Combined With Chemical Ablation in the Treatment of Uterine Fibroids: A Prospective, Multicenter Study","Inclusion Criteria:\n\n1. A definitive diagnosis of uterine fibroids confirmed by magnetic resonance imaging (MRI) and ultrasonography, with the International Federation of Gynecology and Obstetrics (FIGO) classification 0-6;\n2. At least one of the following symptoms: menorrhagia, secondary anemia, abdominal\u002Fpelvic pain, or compression symptoms;\n3. Absence of perimenopausal signs;\n4. A safe transabdominal puncture route accessible under imaging guidance.\n\nExclusion Criteria:\n\n1. Suspicion of malignancy on ultrasound or MRI that cannot be ruled out (e.g., uterine sarcoma; uterine fibroids coexisting with cervical, endometrial, or ovarian cancer; or other gynecological malignancies);\n2. Uterine fibroids with coexisting adenomyosis;\n3. Menstrual, gestational, or lactational period;\n4. Uterine fibroids classified as FIGO type 7;\n5. Known allergy to alcohol, lauromacrogol, or related sclerosing agents;\n6. Absence of a safe percutaneous puncture route (e.g., lesion adherent to critical structures - bowel, bladder, or major vessels - that cannot be safely separated);\n7. Uncontrolled acute pelvic inflammatory disease;\n8. Significant hepatic, renal, or other major organ dysfunction;\n9. Severe coagulopathy, defined as platelet count \\\u003C50 × 10⁹\u002FL, prothrombin time \\>25 s, or prothrombin activity \\\u003C40%;\n10. History of other malignancies;\n11. Participation in another clinical trial within 1 month prior to informed consent;\n12. Any other condition deemed by the investigator to render the subject unsuitable for participation in this trial.","FEMALE",{"count":17,"type":18},248,"ESTIMATED","INTERVENTIONAL",[21],"NA","Uterine fibroids are the most common benign tumors in women of reproductive age, with a prevalence of 20%-50%, often causing menorrhagia, anemia, pelvic pain, and pressure symptoms that markedly impair quality of life. Current treatments include pharmacological therapy (GnRH-a, mifepristone) - effective temporarily but with high recurrence after discontinuation; surgical myomectomy or hysterectomy - definitive yet invasive, with prolonged recovery and potential fertility compromise; and minimally invasive therapies such as uterine artery embolization (UAE), high-intensity focused ultrasound (HIFU), and microwave ablation (MWA), which are increasingly favored for their minimal invasiveness and rapid recovery.\n\nMWA delivers thermal energy via a percutaneously inserted antenna under ultrasound guidance, inducing coagulative necrosis of fibroid tissue through temperatures exceeding 60°C. Advantages include minimal trauma (\\~2 mm puncture), rapid recovery (discharge within 1-2 days), uterine preservation, and negligible ovarian impact. However, a key limitation is the heat sink effect: in hypervascular fibroids, flowing blood dissipates thermal energy, resulting in incomplete ablation, prolonged procedural time, and higher energy requirements - particularly challenging for fibroids \\>5 cm in diameter.\n\nChemical ablation involves intralesional injection of a sclerosing agent (e.g., lauromacrogol), which damages vascular endothelial cells, causing vascular occlusion, thrombosis, ischemic necrosis, and direct membrane disruption that accelerates apoptosis. Theoretically, pre-ablation chemical sclerotherapy may occlude feeding vessels, attenuate the heat sink effect, and enhance subsequent thermal ablation efficiency. Supporting this concept, an ex vivo bovine liver study demonstrated that pre-injection of 5 mL of 99.5% ethanol around the electrode prior to radiofrequency ablation produced a significantly larger ablation zone at equivalent energy levels compared with ablation alone. Small-sample clinical studies, including a prospective cohort from Shanghai Tenth People's Hospital, have preliminarily explored combined chemical ablation plus MWA for uterine fibroids, suggesting improved ablation rates and shorter procedural times, though findings require validation through high-quality randomized controlled trials.\n\nTherefore, the investigators conducted this multicenter, prospective, randomized controlled trial to rigorously compare the safety (incidence and severity of adverse events) and efficacy (fibroid volume reduction rate, symptom improvement, quality-of-life outcomes) of MWA alone versus MWA combined with chemical ablation. This study aims to clarify the clinical value of the combined approach and provide high-quality, evidence-based data to guide the optimal selection of minimally invasive treatment strategies for uterine fibroids.",[24,25,26],"Uterine Fibroids (UF)","Microwave Ablation","Ultrasound","NOT_YET_RECRUITING","2026-08-04",{"date":30,"type":31},"2026-08-10","ACTUAL",{"date":33,"type":18},"2026-08-01",{"date":35,"type":18},"2028-08-30",{"name":37,"class":38},"Peking University Aerospace Center Hospital","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":53,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":39},"100613645","the-correlation-and-mechanistic-study-of-ggcx-gene-with-prognosis-in-acute-ischemic-stroke-100613645","NCT07269288","The Correlation and Mechanistic Study of GGCX Gene With Prognosis in Acute Ischemic Stroke","Study Protocol on the Correlation and Mechanistic Study of GGCX Gene With Prognosis in Acute Ischemic Stroke","* Inclusion Criteria\n\n  (1) Inclusion Criteria for Acute Ischemic Stroke Patients:\n  1. Aged between 18 and 85 years.\n  2. Diagnosed with ischemic stroke (in accordance with the \"Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023,\" including TOAST etiological\u002Fpathogenic subtypes: large-artery atherosclerosis (LAA), cardioembolism (CE), small-artery occlusion (SAO), stroke of other determined etiology (SOE), and stroke of undetermined etiology (SUE)).\n  3. Acute onset, with symptoms occurring within 72 hours and being the first episode.\n  4. Voluntary participation with signed informed consent.\n\n  (2) Inclusion Criteria for Healthy Controls: 1) Healthy control population matched for age, gender, and risk factors (including personal and family history).\n* Exclusion Criteria\n\n  (1) Exclusion Criteria for Healthy Controls:\n  1. Patients with cerebrovascular diseases occurring within 72 hours.\n  2. Pregnant or lactating patients.\n\n  (2) Exclusion Criteria for Acute Ischemic Stroke Patients:\n  1. Other types of stroke, including hemorrhagic stroke, mixed stroke, and tumor-related stroke patients.\n  2. Patients with coagulation disorders or other hematologic diseases.\n  3. Patients with severe cardiovascular, pulmonary, or hepatic diseases.\n  4. Renal dysfunction.\n  5. Cancer patients.\n  6. Patients with active gastric ulcers or gastric bleeding.\n  7. Pregnant or lactating patients.",true,"ALL","18 Years","85 Years",{"count":52,"type":18},1500,"12 Months","OBSERVATIONAL","This observational study aims to investigate the impact of GGCX gene mutations and GGCX levels on stroke prognosis in patients with ischemic stroke, as well as their correlation. The main issues are:\n\nWhat is the relationship and potential mechanism between GGCX gene mutations and their expression levels and the composite prognosis of recurrence, death, and bleeding events in patients with ischemic stroke? Collect blood samples from enrolled ischemic stroke patients for genetic testing, and conduct follow-up visits at 3, 6, and 12 months after discharge to evaluate clinical prognosis outcomes. This will answer questions about the relationship and mechanism between GGCX gene and patient prognosis.",[57],"Acute Ischemic Stroke",[59],"Stroke","2025-11-25",{"date":62,"type":31},"2025-12-08",{"date":64,"type":18},"2026-01-25",{"date":66,"type":18},"2028-02-28",{"name":37,"class":38},""]